NewsBenzingaAbbVie Reports Topline Results From Phase 3 INTREPID Study Evaluating Lutikizumab, Investigational Dual-Variable-Domain IL 1α/1β Antagonist, In Hidradenitis Suppurativa; Study Met Primary Endpoint And 8 Ranked Secondary Endpoints AbbVie Reports Topline Results From Phase 3 INTREPID Study Evaluating Lutikizumab, Investigational Dual-Variable-Domain IL 1α/1β Antagonist, In Hidradenitis Suppurativa; Study Met Primary Endpoint And 8 Ranked Secondary Endpoints Benzinga 2026.10.22 13:08 (GMT+0) Open on Benzinga Other news LDP: The Family Favorite But Not Enough (NYSE:LDP) Betterware: Tupperware Looks Better, But Jafra Looks Worse (NYSE:BWMX) Palo Alto CEO Nikesh Arora Warns Companies to Assume They Will Get ‘Breached’ and Fix Their ‘Technology Debt’ as AI Uncovers Critical Software Flaws Tower Semiconductor: The Silicon Photonics Opportunity Is Taking Shape (NASDAQ:TSEM) Enovis Screens Cheap, But There Is A Continued M&A Overhang (NYSE:ENOV) Coeur Mining: The Cost Trick Every Silver Investor Should Understand (NYSE:CDE)
Palo Alto CEO Nikesh Arora Warns Companies to Assume They Will Get ‘Breached’ and Fix Their ‘Technology Debt’ as AI Uncovers Critical Software Flaws
